Research
M1/M4 Agonist Relieved Schizophrenia Symptoms in Mid-Stage Trial
The Brief
- ML-007C-MA, an investigational muscarinic M1/M4 receptor agonist, is a combination of betovumeline and fesoterodine fumarate.
- In a mid-stage trial, it significantly improved schizophrenia symptoms in adults who had an acute exacerbation of psychosis.
- The source reports these trial data but is only a brief excerpt, so the full trial details are not available here.
Why it matters
The result adds evidence that muscarinic M1/M4 agonism may treat schizophrenia symptoms, a mechanism distinct from current dopamine-focused antipsychotics. It is still an investigational mid-stage finding.
Who’s affected
- psychiatrists and clinicians who treat schizophrenia
- researchers in neuropsychopharmacology and drug development
- #schizophrenia
- #psychiatry
- #muscarinic receptors
- #clinical trial
- #drug development
(MedPage Today) -- ML-007C-MA, an investigational muscarinic M1/M4 receptor agonist that combines betovumeline and fesoterodine fumarate, significantly improved schizophrenia symptoms in adults who had an acute exacerbation of psychosis, data from...